Abbott to Acquire Exact Sciences for $21 Billion
Abbott Laboratories announced its plan to acquire Exact Sciences, a cancer diagnostics company, in a deal valued at approximately $21 billion in equity. Abbott will pay $105 per share in cash to Exact Sciences shareholders, representing a premium of about 22% over Exact Sciences' previous closing price.
Transaction Details
- The deal values Exact Sciences at around $21 billion in equity, with a total enterprise value nearing $23 billion when including estimated net debt of about $1.8 billion, which Abbott will assume.
- Shares of Exact Sciences rose more than 17% in premarket trading following the announcement, reflecting positive investor reception.
- The acquisition is expected to finalize by the second quarter of 2026, after which Exact Sciences will operate as a subsidiary under Abbott.
Strategic Importance
Exact Sciences brings key cancer screening products to Abbott, notably the Cologuard test, a non-invasive colorectal cancer screening that patients can perform at home by mailing a stool sample to a lab. This contrasts with traditional colonoscopy methods.
Additionally, Exact Sciences offers the Oncotype DX test for early-stage breast cancer detection, expanding Abbott’s diagnostics portfolio.
"BREAKING: We’re acquiring @ExactSciences, a leader in cancer diagnostics. Together, we’ll transform cancer care through early detection and the support of personalized cancer treatment."
Financial and Market Impact
- Exact Sciences generates yearly revenues estimated at over $3 billion, which will contribute to Abbott's diagnostics sales potentially exceeding $12 billion annually.
- The acquisition diversifies Abbott’s healthcare offerings, especially as its diagnostics division faces revenue declines in areas such as COVID-19 testing.
Leadership and Operations
After the acquisition, Exact Sciences will maintain its headquarters in Madison, Wisconsin, with CEO Kevin Conroy continuing in an advisory capacity.
Author's summary: Abbott's $21 billion acquisition of Exact Sciences marks a strategic expansion into advanced cancer diagnostics, emphasizing at-home screening innovation and boosting Abbott's diagnostics revenue potential.
More News
- [Les structures causales en français : exprimer la cause]
- OFFICIAL RACE PROGRAMME - 2025 Abu Dhabi Grand Prix
- ‘My heart is broken’: Domestic worker mourns sister who died in Hong Kong fire
- Etihad’s A380 to Tokyo in Summer 2026
- November Routes Roundup: Etihad Airways Launches Abu Dhabi–Tokyo A380 Service
- Etihad Airways Adds New 8-Hour Airbus A321LR Flights To Europe
- 01 – Air Libre - Podcasts
- ‘Reviewing it’: Hegseth on releasing video of Caribbean strike; survivors died on alleged drug boat
- « Le commerce en centre-ville n’est pas une cause perdue »
- Steve Cropper, Stax Records and Blues Brothers Guitarist, Dies at 84